CXCR4-a prognostic and clinicopathological biomarker for pancreatic ductal adenocarcinoma: A meta-analysis

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Krieg, Andreas ^a   Riemer, Jasmin C ^a   Telan, Leila A ^a   Gabbert, Helmut E ^a   Knoefel, Wolfram T ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHEMOKINE RECEPTOR CXCR4; FLUOROURACIL; GEMCITABINE; TEGAFUR; URACIL; CXCR4 PROTEIN, HUMAN; TUMOR MARKER;

ADJUVANT CHEMORADIOTHERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; HUMAN; METASTASIS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PROTEIN EXPRESSION; SYSTEMATIC REVIEW; CARCINOMA, PANCREATIC DUCTAL; KAPLAN MEIER METHOD; META ANALYSIS; METABOLISM; MORTALITY; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

BIOMARKERS, TUMOR; CARCINOMA, PANCREATIC DUCTAL; HUMANS; KAPLAN-MEIER ESTIMATE; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, CXCR4;

EID: 84939239210     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130192     Document Type: Article

References (57)

1. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014. Available from: http://seer.cancer.gov/csr/1975-2011.
2. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010; 7(3):163-72. PMID:20101258. doi:10.1038/nrclinonc.2009.236
3. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15(6):2403-13. PMID:9196156.
4. Vaccaro V, Sperduti I, Milella M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 365(8):768-9; author reply 9. PMID:21864184. doi:10.1056/NEJMc1107627#SA1
5. Bacolod MD, Barany F. Molecular profiling of colon tumors: the search for clinically relevant biomarkers of progression, prognosis, therapeutics, and predisposition. Ann Surg Oncol. 18(13):3694-700. PMID:21347779. doi:10.1245/s10434-011-1615-5
6. Gebauer F, Tachezy M, Effenberger K, von Loga K, Zander H, Marx A, et al. Prognostic impact of CXCR4 and CXCR7 expression in pancreatic adenocarcinoma. J Surg Oncol. 104(2):140-5. PMID:21520098. doi:10.1002/jso.21957
7. Schimanski CC, Schwald S, Simiantonaki N, Jayasinghe C, Gonner U, Wilsberg V, et al. Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res. 2005; 11(5):1743-50. PMID:15755995.
8. Ingold B, Simon E, Ungethum U, Kuban RJ, Muller BM, Lupp A, et al. Vascular CXCR4 expression - a novel antiangiogenic target in gastric cancer? PLoS One. 5(4):e10087. PMID:20386750. doi:10.1371/journal.pone.0010087
9. Loetscher M, Geiser T, O'Reilly T, Zwahlen R, Baggiolini M, Moser B. Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes. J Biol Chem. 1994; 269 (1):232-7. PMID:8276799.
10. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature. 1996; 382(6594):829-33. PMID:8752280.
11. Ratajczak MZ, Zuba-Surma E, Kucia M, Reca R, Wojakowski W, Ratajczak J. The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia. 2006; 20 (11):1915-24. PMID:16900209.
12. Billadeau DD, Chatterjee S, Bramati P, Sreekumar R, Shah V, Hedin K, et al. Characterization of the CXCR4 signaling in pancreatic cancer cells. Int J Gastrointest Cancer. 2006; 37(4):110-9. PMID:18175225. doi:10.1007/s12029-007-0011-7
13. Mori T, Doi R, Koizumi M, Toyoda E, Ito D, Kami K, et al. CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol Cancer Ther. 2004; 3(1):29-37. PMID:14749473.
14. Saur D, Seidler B, Schneider G, Algul H, Beck R, Senekowitsch-Schmidtke R, et al. CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer. Gastroenterology. 2005; 129(4):1237-50. PMID:16230077.
15. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res. 2008; 14(9):2519-26. PMID:18451212. doi:10.1158/1078-0432.CCR-07-2223
16. Liao WC, Wang HP, Huang HY, Wu MS, Chiang H, Tien YW, et al. CXCR4 expression predicts early liver recurrence and poor survival after resection of pancreatic adenocarcinoma. Clin Transl Gastroenterol. 3:e22. PMID:23238349. doi:10.1038/ctg.2012.18
17. Marechal R, Demetter P, Nagy N, Berton A, Decaestecker C, Polus M, et al. High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. Br J Cancer. 2009; 100 (9):1444-51. PMID:19352387. doi:10.1038/sj.bjc.6605020
18. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J. 2001; 18(4):705-19. PMID:11716177.
19. Krieg A, Baseras B, Tomczak M, Verde PE, Stoecklein NH, Knoefel WT. Role of survivin as prognostic and clinicopathological marker in gastric cancer: a meta-analysis. Mol Biol Rep. 40(9):5501-11. PMID:23948878. doi:10.1007/s11033-013-2650-z
20. Krieg A, Werner TA, Verde PE, Stoecklein NH, Knoefel WT. Prognostic and clinicopathological significance of survivin in colorectal cancer: a meta-analysis. PLoS One. 8(6):e65338. PMID:23755220. doi:10.1371/journal.pone.0065338
21. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMID:17555582.
22. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997; 127(9):820-6. PMID:9382404.
23. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21 (11):1539-58. PMID:12111919.
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. PMID:3802833.
25. Zhong W, Chen W, Zhang D, Sun J, Li Y, Zhang J, et al. CXCL12/CXCR4 axis plays pivotal roles in the organ-specific metastasis of pancreatic adenocarcinoma: A clinical study. Exp Ther Med. 4(3):363-9. PMID:23181100.
26. Guo J, Lou W, Ji Y, Zhang S. Effect of CCR7, CXCR4 and VEGF-C on the lymph node metastasis of human pancreatic ductal adenocarcinoma. Oncol Lett. 5(5):1572-8. PMID:23761820.
27. Heinrich EL, Lee W, Lu J, Lowy AM, Kim J. Chemokine CXCL12 activates dual CXCR4 and CXCR7- mediated signaling pathways in pancreatic cancer cells. J Transl Med. 10:68. PMID:22472349. doi:10.1186/1479-5876-10-68
28. Roy I, Zimmerman NP, Mackinnon AC, Tsai S, Evans DB, Dwinell MB. CXCL12 chemokine expression suppresses human pancreatic cancer growth and metastasis. PLoS One. 9(3):e90400. PMID:24594697. doi:10.1371/journal.pone.0090400
29. Welsch T, Keleg S, Bergmann F, Degrate L, Bauer S, Schmidt J. Comparative analysis of tumorbiology and CD133 positivity in primary and recurrent pancreatic ductal adenocarcinoma. Clin Exp Metastasis. 2009; 26(7):701-11. PMID:19488831. doi:10.1007/s10585-009-9269-4
30. Wang B, Sun S, Liu Z. Analysis of dysregulation of immune system in pancreatic cancer based on gene expression profile. Mol Biol Rep. 41(7):4361-7. PMID:24619357. doi:10.1007/s11033-014-3307-2
31. Van den Broeck A, Vankelecom H, Van Delm W, Gremeaux L, Wouters J, Allemeersch J, et al. Human pancreatic cancer contains a side population expressing cancer stem cell-associated and prognostic genes. PLoS One. 8(9):e73968. PMID:24069258. doi:10.1371/journal.pone.0073968
32. Marchesi F, Monti P, Leone BE, Zerbi A, Vecchi A, Piemonti L, et al. Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res. 2004; 64(22):8420-7. PMID:15548713.
33. Maeda S, Shinchi H, Kurahara H, Mataki Y, Maemura K, Sato M, et al. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer. 2008; 98(8):1389-97. PMID:18349830. doi:10.1038/sj.bjc.6604307
34. Jiang YM, Li G, Sun BC, Zhao XL, Zhou ZK. Study on the relationship between CXCR4 expression and perineural invasion in pancreatic cancer. Asian Pac J Cancer Prev. 15(12):4893-6. PMID:24998559.
35. Park JK, Kim MA, Ryu JK, Yoon YB, Kim SW, Han HS, et al. Postoperative prognostic predictors of pancreatic ductal adenocarcinoma: clinical analysis and immunoprofile on tissue microarrays. Ann Surg Oncol. 19(8):2664-72. PMID:22395988. doi:10.1245/s10434-012-2277-7
36. Bachet JB, Marechal R, Demetter P, Bonnetain F, Couvelard A, Svrcek M, et al. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Ann Oncol. 23(9):2327-35. PMID:22377565. doi:10.1093/annonc/mdr617
37. Cui K, Zhao W, Wang C, Wang A, Zhang B, Zhou W, et al. The CXCR4-CXCL12 pathway facilitates the progression of pancreatic cancer via induction of angiogenesis and lymphangiogenesis. J Surg Res. 171(1):143-50. PMID:20462600. doi:10.1016/j.jss.2010.03.001
38. Koshiba T, Hosotani R, Miyamoto Y, Ida J, Tsuji S, Nakajima S, et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res. 2000; 6(9):3530-5. PMID:10999740.
39. Kure S, Matsuda Y, Hagio M, Ueda J, Naito Z, Ishiwata T. Expression of cancer stem cell markers in pancreatic intraepithelial neoplasias and pancreatic ductal adenocarcinomas. Int J Oncol. 41(4):1314-24. PMID:22824809. doi:10.3892/ijo.2012.1565
40. Wang Z, Ma Q, Li P, Sha H, Li X, Xu J. Aberrant expression of CXCR4 and beta-catenin in pancreatic cancer. Anticancer Res. 33(9):4103-10. PMID:24023356.
41. Wehler T, Wolfert F, Schimanski CC, Gockel I, Herr W, Biesterfeld S, et al. Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease. Oncol Rep. 2006; 16 (6):1159-64. PMID:17089032.
42. Chow MT, Luster AD. Chemokines in Cancer. Cancer Immunol Res. 2(12):1125-31. PMID:25480554. doi:10.1158/2326-6066.CIR-14-0160
43. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol. 2004; 14(3):171-9. PMID:15246052.
44. Schioppa T, Uranchimeg B, Saccani A, Biswas SK, Doni A, Rapisarda A, et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med. 2003; 198(9):1391-402. PMID:14597738.
45. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 16(11):2927-31. PMID:20484021. doi:10.1158/1078-0432.CCR-09-2329
46. Lombardi L, Tavano F, Morelli F, Latiano TP, Di Sebastiano P, Maiello E. Chemokine receptor CXCR4: role in gastrointestinal cancer. Crit Rev Oncol Hematol. 88(3):696-705. PMID:24120239. doi:10. 1016/j.critrevonc.2013.08.005
47. Han M, Lv S, Zhang Y, Yi R, Huang B, Fu H, et al. The prognosis and clinicopathology of CXCR4 in gastric cancer patients: a meta-analysis. Tumour Biol. 35(5):4589-97. PMID:24464926. doi:10.1007/s13277-013-1603-4
48. Liu CF, Liu SY, Min XY, Ji YY, Wang N, Liu D, et al. The prognostic value of CXCR4 in ovarian cancer: a meta-analysis. PLoS One. 9(3):e92629. PMID:24658065. doi:10.1371/journal.pone.0092629
49. Lv S, Sun B, Zhong X, Dai C, Wang W, Ma X, et al. The Clinical Implications of Chemokine Receptor CXCR4 in Grade and Prognosis of Glioma Patients: A Meta-Analysis. Mol Neurobiol. PMID:25213993.
50. Lv S, Yang Y, Kwon S, Han M, Zhao F, Kang H, et al. The association of CXCR4 expression with prognosis and clinicopathological indicators in colorectal carcinoma patients: a meta-analysis. Histopathology. 64(5):701-12. PMID:24422942. doi:10.1111/his.12321
51. Tang B, Tang F, Li Y, Yuan S, Li B, Wang Z, et al. Clinicopathological Significance of CXCR4 Expression in Renal Cell Carcinoma: A Meta-Analysis. Ann Surg Oncol. PMID:25249257.
52. Wu J, Wu X, Liang W, Chen C, Zheng L, An H. Clinicopathological and prognostic significance of chemokine receptor CXCR4 overexpression in patients with esophageal cancer: a meta-analysis. Tumour Biol. 35(4):3709-15. PMID:24326770. doi:10.1007/s13277-013-1490-8
53. Zhang Z, Ni C, Chen W, Wu P, Wang Z, Yin J, et al. Expression of CXCR4 and breast cancer prognosis: a systematic review and meta-analysis. BMC Cancer. 14:49. PMID:24475985. doi:10.1186/1471-2407-14-49
54. Boldajipour B, Mahabaleshwar H, Kardash E, Reichman-Fried M, Blaser H, Minina S, et al. Control of chemokine-guided cell migration by ligand sequestration. Cell. 2008; 132(3):463-73. PMID:18267076. doi:10.1016/j.cell.2007.12.034
55. Dambly-Chaudiere C, Cubedo N, Ghysen A. Control of cell migration in the development of the posterior lateral line: antagonistic interactions between the chemokine receptors CXCR4 and CXCR7/RDC1. BMC Dev Biol. 2007; 7:23. PMID:17394634.
56. Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood. 2009; 113(24):6085-93. PMID:19380869. doi:10.1182/blood-2008-12-196618
57. Luker KE, Lewin SA, Mihalko LA, Schmidt BT, Winkler JS, Coggins NL, et al. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells. Oncogene. 31(45):4750-8. PMID:22266857. doi:10.1038/onc.2011.633